Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.

Treatment of Neurohypophyseal Diabetes Insipidus

Oiso, Yutaka, Robertson, Gary L., Nørgaard, Jens Peter, Juul, Kristian Vinter · 2013 · The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: In recent years, there have been several improvements in the treatment of neurohypophyseal diabetes insipidus (DI). They include new formulations of the vasopressin analog, desmopressin; a better understanding of the effect of fluid intake on dosing; and more information about treatments of infants, children, and pregnant women who present special challenges. This review aims to summarize past and current information relative to the safety and efficacy of treatments for the types of DI caused by a primary deficiency of vasopressin. EVIDENCE ACQUISITION: The review is based on publications identified primarily by a PubMed search of the international literature without limitations of date. EVIDENCE SYNTHESIS: In acute settings where fluid intake is determined by factors other than thirst, desmopressin should be given iv in doses that have a short duration of action and can be adjusted quickly in accordance with changes in hydration as indicated by plasma sodium. In ambulatory patients, the oral formulations (tablet or melt) are preferred for their convenience. If fluid intake is regulated normally by the thirst mechanism, the tablets or melt can be taken safely 1 to 3 times a day in doses sufficient to completely eliminate the polyuria. However, if fluid intake consistently exceeds replacement needs as evidenced by the development of hyponatremia, the dose should be reduced to allow higher than normal rates of urine output or intermittent breakthrough diuresis. This regimen is often indicated in infants or children because their rate of fluid intake tends to be greater than in adults. In all cases, the appropriate dose should be determined by titration, owing to considerable interindividual differences in bioavailability and antidiuretic effect. CONCLUSIONS: Desmopressin can provide effective and safe therapy for all patients with neurohypophyseal or gestational DI if given in doses and by a route that takes into account the determinants of fluid intake.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2013-2326

Cites

86 of 86 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 84 references

Cited by

See all 103

Metadata

Authors
Oiso, Y., Robertson, G. L., Nørgaard, J. P., & Juul, K. V.
Affiliations
  • Ghent University (BE)
  • Northwestern University (US)
  • Ferring Pharmaceuticals (Denmark) (DK)
Corresponding author
Juul, Kristian Vinter
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2013-10
Volume
98
Issue
10
Pages
3958-3967
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2154417986
Cited by
101
References
84
Citations by year
2026: 5 · 2025: 6 · 2024: 4 · 2023: 6 · 2022: 8 · 2021: 7 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 10 · 2016: 7 · 2015: 7 · 2014: 13 · 2013: 1
FWCI
7.55
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Funders
  • Universiteit Gent
  • Faculty of Medicine and Health, University of Sydney
Topics
  • Health Sciences › Medicine › Nephrology › Electrolyte and hormonal disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
Keywords
desmopressin, vasopressin analogue, fluid intake, hyponatremia, polyuria, dose titration, infants, children, pregnancy, gestational diabetes insipidus, plasma sodium
MeSH terms
Deamino Arginine Vasopressin, Humans, Polyuria, Treatment Outcome, Diabetes Insipidus, Neurogenic, Antidiuretic Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Treatment of Neurohypophyseal Diabetes Insipidus. https://app.cochat.ai/papers/10.1210/jc.2013-2326
The paper
Oiso, Y., Robertson, G. L., Nørgaard, J. P., & Juul, K. V. (2013). Treatment of Neurohypophyseal Diabetes Insipidus. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2013-2326

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.